Objectives: To investigate and compare symptom changes and quality of life (QOL) in non equol producer postmenopausal women after consuming daidzein supplementation.
INTRODUCTION
Menopause is defined as cessation of menstruation, which represents the end of ovulation, causes reduction in estradiol production [1, 2] . Average menopausal age varies in range between 50 and 52 years old [1] . By 2012 in Indonesia, 44% of women underwent menopausal phase by the age of 48-49 years old [3] . If life expectancy in Indonesian women was 73 years old, it implied women would spent one-third of her life cycle within menopausal phase, dealing with its consequences. This triggers awareness toward action to elevate women's quality of life (QOL) in this concerning period [3, 4] .
Vasomotor symptoms, physical, psychological, and sexual dysfunction became major complains due to physiological changes during menopause [4] [5] [6] . Duration and intensity of these symptoms vary among women. In European countries, complaints of sleep disturbance, depression, and vasomotor symptoms frequently found. On the other hand, Australian women mostly experience vasomotor symptoms and sexual dysfunction [7] . Interestingly, studies in Asia held in 2006 discovered that vasomotor symptoms were not the major concern but muscular and joint problems followed by memory derangement [8] . In Indonesia, only 5% of women complained of hot flushes, while 93% had joint muscular symptoms [8] .
Epidemiology studies concluded Asian women, who consumed soy, experience lesser menopausal symptoms compared to Western women [9] [10] [11] [12] [13] . Soybean possesses Daidzein, one form of isoflavone substance. Within intestines, daidzein degradation conducted by intestinal microbes and changed into main metabolite substance, equol. Equol has estrogen-like structure and its affinity is greater toward beta estrogen receptor [14] [15] [16] .
To overcome climacteric symptoms, some women chose to have hormonal or non-hormonal treatment [17] [18] [19] [20] . Despite its subtle advantage, many Asian women prefer to consume pill of natural substance rather than hormonal pill to cure the according symptoms [17] . Even though hormonal therapy is the most effective way to reduce climacteric symptoms, some women are reluctant to undergo hormonal treatment due to society belief that it may cause cancer; the high spending cost of hormonal treatment interferes tendency to choose another alternative, such as herbal [18] [19] [20] [21] [22] [23] . Asian Menopause Survey in 2010 declared that only 19% from 1000 menopause women have hormone pill as their chosen treatment [17] .
Soy-consuming habit forms a hypothesis that Asian women has ability to produce equol from soybean daidzein isoflavone which effects positively in reducing climacteric symptoms [11] . The study by Ishiwata, in 2009, stated that equol supplementation for 12 weeks significantly reduces mood alteration symptoms due to menopause compared to control group consisted of pre-and post-menopause [9] . Usage of daidzein supplementation is to elevate QOL in menopausal women who experience climacteric symptoms without worrying side effects that may occur unlike hormonal treatment [24] .
METHODS
This research was randomized controlled trial and subjects were into two groups. The subjects received randomized allocation of treatment, calcium glycerophosphate 500 mg+vitamin D3 35 IU as control group, and calcium glycerophosphate 500 mg+vitamin D3 140 IU along with daidzein 120 mg as treatment group for 8 weeks. This was a singleblind researchers acknowledge subject allocation and subjects did not aware of which group they were belong. The subjects were women between 45 and 65 years old who underwent natural menopausal state had no menstruation at least 12-month after last period. Respondents who had been actively smoking, the previously under hormonal therapy for the last 6 weeks before test were taken, allergic to drug substances, liver and/or renal dysfunction, history of breast, endometrium, and/or cervix were excluded.
The samples enrolled by consecutive sampling. Researcher obtained subjects from local menopause association and each had symptoms according to questionnaire filled by subject until reach targeted number of sample and used block randomization. After consenting, peripheral blood was taken to measure daidzein and equol level using HPLC analysis. Intention to treat method was implemented in this research. This research was approved by Ethic Committee in Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital.
RESULTS
A total of 41 respondents filled out questionnaire given and passed inclusion criteria. One respondent rejected consent. Daidzein supplementation was given to 19 subjects (47.5%) and 21 subjects received control tablet (Table 1) .
During research, four subjects dropped out treatment. There were no side effects reported from treatment group. From these selected samples, none was equol producers (Table 2) .
From characteristic demography table, respondents' median age was 53-year-old in control group and 57-year-old in the treatment group with age of menopause consecutively were 50-49 years old. Most disturbing climacteric symptoms were physical domain. Based on MenQOL questionnaire, joint and muscular pain became the most disturbing complaint. There was no significant difference found in menopausal symptoms in control and treatment groups before intervention (Table 3) .
Even though participants were not equol producers, research observed significant reduction clinically and statistically from menopause complaint score in all domains in the treatment group after 8 weeks supplementation (Table 4) .
This phenomenon did not occur in control group. Yet, menopause score reduction between before and after supplementation did not statistically significant compared to control group with p>0.05 (Table 5) .
DISCUSSION
Based on descriptive data, the most complained climacteric symptoms were physical domain, followed by sexual, vasomotor, and psychosocial symptoms. 87.5% of respondents had experienced joint and muscular pain. Same result was also seen in the study by Pan-Asia Menopause, which stated that 86.3% of Asian women underwent joint and muscular problem during menopause [8, 24, 25] . Multivariate analysis by Kalarhoudi mentioned that frequent exercise, physical activity, educational background, satisfaction in family life, income, age, and duration of menopause were influencing factors that determine quality life of menopausal women [26] .
Referred to Hong, around 50-60% of Asian women produced equol. Subject consumed soy-contain diet at least twice a week in average although it was not be recorded on food recall. Yet, interestingly, laboratory examination could not detect any equol in blood plasma, therefore all participants were in homogen category, the equol non producer group [26, 27] . Setchell stated that duration and amount of daidzein-containing food, type of intestinal microbiota population, such as bacteria with ability to reduce sulfa, amount of polyunsaturated fatty acid, and vitamin A and E in food influenced level of equol in vivo. Elimination of equol within plasma was 7-8 hrs [28] . This may be the reason the previous studies conducted "challenge" by giving soycontaining food prior examining respondent's equol level just to be assessed by urine collection or blood withdraw. Even so, the previous similar study by Botefilia et al., using isoflavone 120 mg without prior soy challenge, 62% of respondents were equol producers before supplementation be given [29] .
The food recall was not conducted in this research and this raised bias because contain of substance could not be measured quantitatively. Equol level after supplementation was not measured, thus researcher could not detect changes in equol level. Yet, study by Botefilia et al. stated that there were no significant changes found in equol level between equol-producer and non equol producer before and after supplementing 120 mg daidzein for 6 weeks [29] .
After 8 weeks of treatment and observation, no side effect occurred in supplementing daidzein 120 mg/day. Until recent, no studies had shown any side effect by taking daidzein supplementation. High doses administration of phytochemical shown no effective effect or may not safeand Ikegami's study showed high-dose isoflavone (1 g per kg body weight) in pregnant mouse related to low birth weight to the fetus [30, 31] . Usage of plant-based derived preparations, such as soy isoflavone needs further investigations to reveal its real pharmacological and physiological effect for number of dosage in certain period of administration [32] .
MenQOL assessment of daidzein group showed reduction for 1.73 (±2.84) point in vasomotor domain with CI 95% 0.36-3.10, and p=0.016. This implied that if measurements re-conduct in population, menopause score difference before and after 8 weeks supplementation of daidzein 120 mg, calcium glycerophosphate 500 mg, and vitamin D 140 IU would range between 0.36 and 3.10. Significant reduction occurred in all symptom domains, including overall QOL, as listed in Table 4 . However, this result did not occur in control group. Based on research conducted by Basaria, consumption of 20 g soy in 12 weeks decreased menopausal symptoms in four MenQOL domains [33] .
Other study concluded that most Asian women complained less and milder regarding menopausal symptoms compared to Europeans. Phytoestrogen consumption was believed as the root of this phenomenon [34] . Even though in average, participants consumed soycontaining food more than 2 days a week, lab found to equol in blood plasma. This portrayed that participants had no ability to transform soy isoflavones into its metabolites, equol which is a metabolic degradation by intestinal flora that has proven possesses beneficial impact in menopausal physiological changes [35] . Weakness of this report was no food recall data to measure soy consumption per day quantitatively. This study's strength compared to the previous studies was control group also received active substance due to respondents were patients with complaints. The patient compliance was be guaranteed because field coordinator distributed pills every day and attended pills administration per person. Almost no bias in filling out questionnaires, researchers accompanied each participant and explained each given question. The study analysis with intention to threat, so those who dropped out study remained involve in statistical analysis. Analytical method provided non-bias inspection regarding efficacy from intervention until treatment compliance. The patient compliance in this study represents patient compliance in the community.
CONCLUSION
Research found physical domain, joint and muscular pain, was the most complained menopausal symptoms. According to result, complaints of menopausal symptoms were reduced insignificantly after soy germ isoflavone daidzein for 8 weeks compared to control group. Trial did not record any side effects during supplementation of daidzein 120 mg, glycerophosphate 500 mg, and vitamin D 140 IU. Further investigation is important to understand other factors that may affect ability to produce equol metabolites other than soy consumption. 
